News | February 25, 2026
BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
